IZOZF - Izotropic Launches New Website and Corporate Presentation
(TheNewswire)
V ancouver , BC - TheNewswire - February 19, 2021 - Izotropic Corporation (“ Izotropic ” or the “ Company ”) (C NSX : IZO. CN ) (OTC: IZOZF )(FSE: 1R3 ), a company commercializing true 3D, dedicated breast CTimaging technology for the earlier detection, diagnosis, and treatmentof breast cancers, is pleased to announce it has launched an updatedwebsite ( www.izocorp.com ), which includes anenhanced investor section and a new, comprehensive corporatepresentation ( https://izocorp.com/investors/presentation/ ). Visitors to the website will find a rebranded, upgradedonline experience that includes a video section that will focus onbusiness developments and commercialization topics. A variety of newcontent will be added on a regular basis.
Additionally, visitors will find the new corporatepresentation details how the company is addressing a significant unmetneed in breast imaging with its izoview breast CT platform, an updatedcommercial development pathway, and a detailed overview of theCompany’s workstream activities aimed at increasing time to market.
Izotropic is the only publicly traded company developing a breast CTplatform device with plans to provide solutions for breast cancerscreening, diagnosis, biopsies, treatment, and monitoring.
CEO Robert Thast stated, “The rebranding and launchof the new website and detailed corporate presentation is the firststep in our plans to ramp up awareness for Izotropic in North Americaand beyond. The recent up-listing to the OTCQB VentureMarket has positioned the Company for broader investor visibility inthe U.S. We are also preparing marketing programs aimed at increasingvisibility with breast cancer advocates, consumers and potentialcustomers in the U.S. medical imaging market. The Company isprogressing on every aspect of its business plans and is solidlyfocussed on expediting patient access to our izoview breast CT system.”
The Company also announces a grant of 300,000 stockoptions to consultants and 100,000 stock options to management at anexercise price of $1.08. The stock options are in effect for two yearsand vest immediately.
ON BEHALF OF THE BOARD
For investor relations inquiries contact: For general inquires contact:
Dan Sammartino 1-833-IZOCORP
Phone: 1-778-962-0234 info@izocorp.com
Email: IR@izocorp.com
About Izotropic Corporation
Izotropic Corporation is commercializing dedicatedbreast CT imaging technology for the earlier detection, diagnosis andtreatment of breast cancers. Extensive preliminary studies have foundthat breast CT may be able to routinely detect small breast tumors inthe 3-5 mm size range. The median size of breast cancer found usingmammography is approximately 11 mm. Routinedetection of 3 mm lesions would result in 1.5 year earlier detectionover mammography.
The initial indication for use for breast CT as adiagnostic device has been confirmed. Forthcoming business objectivesinclude identifying additional indications for use, development ofaccessories, and additional products, all aimed at making breast CT anindispensable tool for improving the outcomes of breast cancer.
Additional infor mation aboutIzotropic Corporation can be found on its website at izocorp.com and by reviewing its profile on SEDAR at sedar.com
Forward Looking Statements
This document may contain statements that are“Forward-Looking Statements,” which are based upon the currentestimates, assumptions, projections and expectations of thecompany’s management, business, and its knowledge of the relevantmarket and economic environment in which it operates. The Company hastried, where possible, to identify such information and statements byusing words such as “anticipate,” “believe,” “envision,”“estimate,” “expect,” “intend,” “may,” “plan,”“predict,” “project,” “target,” “potential,”“will,” “would,” “could,” “should,” “continue,”“contemplate” and other similar expressions and derivationsthereof in connection with any discussion of future events, trends orprospects or future operating or financial performance, although notall forward-looking statements contain these identifying words. Thesestatements are not guarantees of performance and involve risks anduncertainties that are difficult to control or predict, and as suchthey may cause future results of the company’s activity to differsignificantly from the content and implications of such statements.Forward-Looking Statements are pertinent only as of the date on whichthey are made, and the company undertakes no obligation to update orrevise any Forward-Looking Statements to reflect new information orthe occurrence of future events or circumstances unless otherwiserequired to do so by law. Neither the companynor its shareholders, officers and consultants, shall be liable forany action and the results of any action taken by any person based onthe information contained herein, including without limitation thepurchase or sale of company securities. Nothing in this documentshould be deemed to be medical or other advice of any kind.
Copyright (c) 2021 TheNewswire - All rights reserved.